Napo Pharmaceuticals yesterday posted a public notice to 340B covered entities about how to obtain 340B pricing on Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs.
Category: Pharma Industry
Biopharmaceutical manufacturer Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients.
Please Login or Become a Paid Subscriber to View this Content
340B hospitals are bracing for a blow tomorrow when drug manufacturer Merck imposes restrictions on 340B discounts when entities use contract pharmacies to dispense drugs to patients.
Please Login or Become a Paid Subscriber to View
U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on
…
Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.
Please Login or Become a Paid Subscriber to View this Content
Drug manufacturer Merck says it is imposing mandatory conditions on 340B pricing when hospitals use contract pharmacies due to “very low” participation in its voluntary 340B program integrity initiative.
Please Login or Become a Paid
Breaking News
Breaking: Merck Will End 340B Contract Pharmacy Pricing for Hospitals That Don’t Share their Claims Data
Drug manufacturer Merck has begun informing 340B covered entities that, effective Sept. 1, it will stop providing 340B pricing to hospitals that partner with 340B contract pharmacies unless the hospitals share 340B claims data with its vendor 340B ESP.
Biopharmaceutical company Apellis has announced a limited distribution plan for Empaveli (pegcetacoplan), a newly approved treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, life-threatening blood disorder.
Please Login
Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.
Please Login
Drug manufacturer Novo Nordisk is giving 340B covered entities refunds for overcharges on two package sizes of its Tresiba FlexTouch insulin pen and on 10 milliliter vials of its Fiasp brand insulin.
Please Login or Become
×
*Sign up for news summaries and alerts from 340B Report